In Vitro Fertilization (IVF) Services Market to Reach Valuation of $25.56 Billion by 2026
13 juil. 2020 11h12 HE
|
Allied Market Research
Portland, OR, July 13, 2020 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research,the global IVF services market generated $12.5 billion in 2018 and is projected to reach...
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
01 juil. 2020 01h00 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – July 1, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
1,000 Miracle Babies Born After Infertile Women Undergo 'Medical Massage' Treatment
20 mai 2020 08h00 HE
|
Clear Passage Therapies
Gainesville, FL, May 20, 2020 (GLOBE NEWSWIRE) -- Developed by a group of leading physicians and cited in several peer-reviewed studies, a pelvic massage developed at Clear Passage® physical therapy...
GoStork Launches Online Platform to Simplify Search for Surrogacy Agencies and Egg Donors
02 mars 2020 09h05 HE
|
gostork.com
NEW YORK, NY , March 02, 2020 (GLOBE NEWSWIRE) -- GoStork, a New York City-based technology company, has announced the launch of an online platform that helps intended parents find, compare, and...
Business Capital Delivers Financing for Bay Area Medical Clinic
12 févr. 2020 05h00 HE
|
Business Capital
SAN FRANCISCO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Business Capital structured and delivered approximately $6MM in senior secured loans for NOVA IVF, a clinic established in 1987, providing in vitro...
ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China
13 janv. 2020 01h00 HE
|
ObsEva SA
Geneva, Switzerland, 13 January 2020 – ObsEva and Yuyuan BioScience Technology (“Yuyuan”) today announced that they have entered into a sublicense agreement to develop and commercialize nolasiban...
Hamilton Thorne to Present at the 2019 Canaccord Genuity Health and Wellness Investor Day
31 oct. 2019 08h30 HE
|
Hamilton Thorne Ltd.
BEVERLY, Mass. and TORONTO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted...
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF
31 oct. 2019 02h00 HE
|
ObsEva SA
FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the...
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
03 sept. 2019 01h00 HE
|
ObsEva SA
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial...
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban
17 juil. 2019 12h00 HE
|
ObsEva SA
Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019 GENEVA, Switzerland and BOSTON, MA - July 17, 2019 – ObsEva SA (NASDAQ:...